PMID- 19454613
OWN - NLM
STAT- MEDLINE
DCOM- 20090908
LR  - 20161125
IS  - 1538-7755 (Electronic)
IS  - 1055-9965 (Linking)
VI  - 18
IP  - 6
DP  - 2009 Jun
TI  - Detection of urothelial bladder cancer cells in voided urine can be improved by a 
      combination of cytology and standardized microsatellite analysis.
PG  - 1798-806
LID - 10.1158/1055-9965.EPI-09-0099 [doi]
AB  - PURPOSE: To evaluate molecular and immunohistochemical markers to develop a 
      molecular grading of urothelial bladder cancer and to test these markers in 
      voided urine samples. EXPERIMENTAL DESIGN: 255 consecutive biopsies from primary 
      bladder cancer patients were evaluated on a tissue microarray. The clinical 
      parameters gender, age, adjacent carcinoma in situ, and multifocality were 
      collected. UroVysion fluorescence in situ hybridization (FISH) was done. 
      Expression of cytokeratin 20, MIB1, and TP53 was analyzed by 
      immunohistochemistry. Fibroblast growth factor receptor 3 (FGFR3) status was 
      studied by SNaPshot mutation detection. Results were correlated with clinical 
      outcome by Cox regression analysis. To assess the predictive power of different 
      predictor subsets to detect high grade and tumor invasion, logistic regression 
      models were learned. Additionally, voided urine samples of 119 patients were 
      investigated. After cytologic examination, urine samples were matched with their 
      biopsies and analyzed for loss of heterozygosity (LOH), FGFR3 mutation, polysomy, 
      and p16 deletion using UroVysion FISH. Receiver operator characteristic curves 
      for various predictor subsets were plotted. RESULTS: In biopsies, high grade and 
      solid growth pattern were independent prognostic factors for overall survival. A 
      model consisting of UroVysion FISH and FGFR3 status (FISH + FGFR3) predicted high 
      grade significantly better compared with a recently proposed molecular grade 
      (MIB1 + FGFR3). In voided urine, the combination of cytology with LOH analysis 
      (CYTO + LOH) reached the highest diagnostic accuracy for the detection of bladder 
      cancer cells and performed better than cytology alone (sensitivity of 88.2% and 
      specificity of 97.1%). CONCLUSIONS: The combination of cytology with LOH analysis 
      could reduce unpleasant cystoscopies for bladder cancer patients.
FAU - Wild, Peter J
AU  - Wild PJ
AD  - Institute of Surgical Pathology, University Hospital Zurich, Zurich, Switzerland. 
      peter.wild@usz.ch
FAU - Fuchs, Thomas
AU  - Fuchs T
FAU - Stoehr, Robert
AU  - Stoehr R
FAU - Zimmermann, Dieter
AU  - Zimmermann D
FAU - Frigerio, Simona
AU  - Frigerio S
FAU - Padberg, Barbara
AU  - Padberg B
FAU - Steiner, Inbal
AU  - Steiner I
FAU - Zwarthoff, Ellen C
AU  - Zwarthoff EC
FAU - Burger, Maximilian
AU  - Burger M
FAU - Denzinger, Stefan
AU  - Denzinger S
FAU - Hofstaedter, Ferdinand
AU  - Hofstaedter F
FAU - Kristiansen, Glen
AU  - Kristiansen G
FAU - Hermanns, Thomas
AU  - Hermanns T
FAU - Seifert, Hans-Helge
AU  - Seifert HH
FAU - Provenzano, Maurizio
AU  - Provenzano M
FAU - Sulser, Tullio
AU  - Sulser T
FAU - Roth, Volker
AU  - Roth V
FAU - Buhmann, Joachim M
AU  - Buhmann JM
FAU - Moch, Holger
AU  - Moch H
FAU - Hartmann, Arndt
AU  - Hartmann A
LA  - eng
PT  - Journal Article
DEP - 20090519
PL  - United States
TA  - Cancer Epidemiol Biomarkers Prev
JT  - Cancer epidemiology, biomarkers & prevention : a publication of the American 
      Association for Cancer Research, cosponsored by the American Society of 
      Preventive Oncology
JID - 9200608
RN  - 0 (Biomarkers, Tumor)
RN  - EC 2.3.2.27 (MIB1 ligase, human)
RN  - EC 2.3.2.27 (Ubiquitin-Protein Ligases)
RN  - EC 2.7.10.1 (Receptor, Fibroblast Growth Factor, Type 3)
SB  - IM
EIN - Cancer Epidemiol Biomarkers Prev. 2010 Feb;19(2):629-30
MH  - Biomarkers, Tumor/*genetics/*urine
MH  - *Cytological Techniques
MH  - DNA Mutational Analysis
MH  - Female
MH  - Humans
MH  - Immunohistochemistry
MH  - In Situ Hybridization, Fluorescence
MH  - Kaplan-Meier Estimate
MH  - Loss of Heterozygosity
MH  - Male
MH  - Microsatellite Repeats/*genetics
MH  - Receptor, Fibroblast Growth Factor, Type 3/biosynthesis/genetics
MH  - Sensitivity and Specificity
MH  - Tissue Array Analysis
MH  - Ubiquitin-Protein Ligases/metabolism
MH  - Urinary Bladder Neoplasms/diagnosis/*genetics/*urine
EDAT- 2009/05/21 09:00
MHDA- 2009/09/09 06:00
CRDT- 2009/05/21 09:00
PHST- 2009/05/21 09:00 [entrez]
PHST- 2009/05/21 09:00 [pubmed]
PHST- 2009/09/09 06:00 [medline]
AID - 1055-9965.EPI-09-0099 [pii]
AID - 10.1158/1055-9965.EPI-09-0099 [doi]
PST - ppublish
SO  - Cancer Epidemiol Biomarkers Prev. 2009 Jun;18(6):1798-806. doi: 
      10.1158/1055-9965.EPI-09-0099. Epub 2009 May 19.